ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

The Delhi High Court has stayed trial court proceedings against Bina Modi and Lalit Bhasin, who were summoned in an assault case filed by Samir Modi. The HC issued notice on their pleas seeking to ...

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE ...

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.

Buying continued at the Pakistan Stock Exchange (PSX), with the benchmark KSE-100 Index gaining over 1,400 points during the opening minutes of trading on Wednesday. At 10am, the benchmark index was ...

Find all the best things to do in Pittsburgh this weekend, from NatureFest to the Pittsburgh Fringe Festival to the Japanese Film Festival.

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a ...

In a groundbreaking milestone for Bangladesh’s fintech industry, aamarPay, a leading payment system operator (PSO), has secured a foreign investment from Simpaisa, a global digital payments ...

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H ...

US FDA approves Novartis Cosentyx for paediatric patients aged 12+ with moderate to severe hidradenitis suppurativa: Basel Monday, March 16, 2026, 14:00 Hrs [IST] Novartis announc ...

Johnson & Johnson (JNJ) on Wednesday announced that the U.S. Food and Drug Administration (FDA) approved Icotyde, a once-daily pill developed with Protagonist Therapeutics (PTGX), as a treatment for ...